BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/14/2025 3:33:47 AM | Browse: 25 | Download: 0
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Perioperative immunotherapy in gastric cancer in the spotlight
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Laura S Pernomian, Maria Fernanda Teixeira, Raphael LC Araujo and Pedro Luiz Serrano Uson Junior |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Raphael LC Araujo, Adjunct Professor, FACS, MD, PhD, Department of Surgery, Carolinas Medical Center, Atrium Health, 1025 Morehead Medical Drive, Charlotte, NC 28204, United States. raphael.l.c.araujo@gmail.com |
| Key Words |
Gastric cancer; Gastroesophageal junction cancer; Perioperative treatment; Neoadjuvant treatment; Chemotherapy; Immunotherapy; Surgery; Gastrectomy |
| Core Tip |
Immunotherapy is reshaping the treatment landscape for resectable gastric and gastroesophageal junction cancers. Despite the established benefit of perioperative leucovorin, oxaliplatin, and docetaxel chemotherapy, complete pathological response rates remain below 15%. Recent phase III trials, including KEYNOTE-585 with pembrolizumab and MATTERHORN with durvalumab, have demonstrated improved pathological responses and event-free survival, particularly in biomarker-enriched subgroups such as microsatellite instability-high or programmed death-ligand 1-positive tumors. This article summarizes the evolving evidence supporting immune checkpoint inhibitors in the perioperative setting and highlights future directions toward biomarker-driven, personalized multimodal therapy for gastric cancer. |
| Citation |
Pernomian LS, Teixeira MF, Araujo RLC, Serrano Uson Junior PL. Perioperative immunotherapy in gastric cancer in the spotlight. World J Clin Oncol 2025; In press |
 |
Received |
|
2025-06-23 10:16 |
 |
Peer-Review Started |
|
2025-06-24 00:37 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2025-07-15 09:55 |
 |
Revised |
|
2025-07-27 21:17 |
 |
Second Decision |
|
2025-11-14 02:42 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-11-14 03:33 |
 |
Articles in Press |
|
2025-11-14 03:33 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345